Alector (NASDAQ:ALEC) Shares Down 4.5%

Alector, Inc. (NASDAQ:ALEC)’s stock price fell 4.5% on Monday . The company traded as low as $5.75 and last traded at $5.75. 39,960 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 700,883 shares. The stock had previously closed at $6.02.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $41.00 price target on shares of Alector in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.50.

Alector Trading Down 5.9 %

The company has a fifty day simple moving average of $6.27 and a two-hundred day simple moving average of $6.23. The stock has a market capitalization of $508.43 million, a P/E ratio of -3.43 and a beta of 0.79.

Alector (NASDAQ:ALEC) last issued its earnings results on Tuesday, February 27th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.31. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. The company had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $8.35 million. As a group, analysts forecast that Alector, Inc. will post -1.89 earnings per share for the current fiscal year.

Insider Activity at Alector

In related news, CEO Arnon Rosenthal sold 18,837 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the completion of the transaction, the chief executive officer now owns 2,000,380 shares in the company, valued at $13,842,629.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Alector news, CEO Arnon Rosenthal sold 18,837 shares of Alector stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $130,352.04. Following the transaction, the chief executive officer now directly owns 2,000,380 shares in the company, valued at $13,842,629.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Gary Romano sold 6,001 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $41,526.92. Following the completion of the sale, the insider now owns 196,313 shares of the company’s stock, valued at $1,358,485.96. The disclosure for this sale can be found here. Insiders have sold 30,554 shares of company stock worth $211,434 in the last ninety days. Company insiders own 14.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ALEC. Quantbot Technologies LP acquired a new stake in shares of Alector during the first quarter worth $25,000. Tower Research Capital LLC TRC raised its stake in shares of Alector by 349.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,571 shares of the company’s stock valued at $28,000 after purchasing an additional 3,554 shares during the period. US Bancorp DE lifted its holdings in shares of Alector by 212.9% in the fourth quarter. US Bancorp DE now owns 6,218 shares of the company’s stock valued at $50,000 after purchasing an additional 4,231 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its position in shares of Alector by 40.3% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 7,914 shares of the company’s stock worth $63,000 after buying an additional 2,273 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Alector during the second quarter worth about $70,000. Institutional investors own 85.83% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.